Sobi announces appointments to strengthen Commercial Organisational Leadership
(Thomson Reuters ONE) -
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced the appointments of
two key pharma veterans - Hege Hellstrom and Rupert Haynes - to further
strengthen its engagement in the rare disease sector. Both senior appointments
will take up their roles over the course of the summer, as Sobi continues to
build its presence in Europe and beyond.
Hege Hellstrom - a Norwegian national and a seasoned leader with more than 20
years of experience, including more than a decade at Baxter and 10 years at
Genzyme - will take up the role of Vice President and Head of Commercial for
Europe, Middle East & North Africa (EMENA). Hellstrom's background encompasses
experience in a variety of national and international roles including Country
General Manager and Business Unit Vice President for Europe covering different
speciality therapeutic areas.
Rupert Haynes, a British national, moves from UCB to take up responsibility for
Sobi's Inflammation business as Head of Global Commercial Operations,
Therapeutic Area Inflammation. Haynes brings more than 20 years of experience
from companies such as Pharmacia, BMS and, most recently, UCB where he was
responsible for the company's marketing excellence programme and played an
instrumental role in securing patient access to Xyrem, part of UCB's orphan
portfolio.
"We are excited to welcome Hege and Rupert to Sobi", says Alan Raffensperger,
Senior Vice President and Chief Operating Officer. "They both bring significant
and extensive experience to their roles. Their individual and combined expertise
will be great additions to our commercial capabilities as an organisation as we
continue to build a sustainable company, able to deliver healthcare solutions to
the rare disease communities."
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(? 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com
For more information - not for publication
Media relations Investor relations
Oskar Bosson, Head of Communications Jörgen Winroth, Vice President, Head of
Investor Relations
T: +46 70 410 71 80 T: +46 8 697 20 00
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
Sobi strengthens Commercial Organisational Leadership:
http://hugin.info/134557/R/1713424/568780.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1713424]
Unternehmensinformation / Kurzprofil:
Datum: 02.07.2013 - 08:01 Uhr
Sprache: Deutsch
News-ID 274926
Anzahl Zeichen: 3926
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 185 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi announces appointments to strengthen Commercial Organisational Leadership"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
